This new study investigated and compared the incidence of disordered eating behavior (DEB) among 2 cohorts of patients with type 1 diabetes (T1D) treated with continuous-subcutaneous insulin infusion ...

A review of published research from the University of Liege, Belgium, reveals a decline in the number of people experiencing allergic reactions to insulin. This is largely due to better purification ...

Continuous subcutaneous insulin infusion (CSII) has become an indispensable modality in the management of type 1 diabetes. This therapy employs an insulin pump to deliver both basal and bolus doses, ...

The FDA has cleared NovoLog (insulin aspart [rDNA origin] injection) from Novo Nordisk for continuous subcutaneous insulin infusion (CSII) by external insulin pump in pediatric patients aged 4-18 ...

Although the initiation of U-500 insulin either via multi-dose injection (MDI) or continuous subcutaneous insulin infusion (CSII) would likely be the task of a diabetes specialist, primary care ...

Two long-acting insulin analogs have been developed for use as "basal" components of insulin treatment regimens: glargine and detemir. (Insulin glargine has US Food and Drug Administration [FDA] ...

Endocrinologists offer updated recommendations to increase glycemic control and avoid complications. Here is a quick summary. The American Association of Clinical Endocrinologists (AACE) has released ...